新药周观点：ESMO即将召开，多个数据披露催化值得关注-20251012

Investment Rating - The report maintains an investment rating of "Outperform" with a target of "A" [5] Core Insights - The report highlights the upcoming ESMO conference as a significant catalyst for the innovative drug sector, with multiple domestic companies expected to disclose important data [3][21] - The report suggests focusing on several key companies and products that are likely to benefit from upcoming catalysts, including academic conferences, business development (BD) realizations, and negotiations for medical insurance [20] Summary by Sections Weekly New Drug Market Review - From October 6 to October 12, 2025, the top five gainers in the new drug sector were Yongtai Bio (+13.47%), Fuhong Hanlin (+3.06%), Keji Pharma (+2.77%), Betta Pharma (+1.57%), and Aidi Pharma (+0.83%). The top five losers were Rongchang Bio (-20.97%), Nuocheng Jianhua (-14.83%), Chuangsheng Group (-11.23%), Yifang Bio (-9.77%), and Kelun Botai (-9.08%) [16][17] Recommended Focus Stocks - The report recommends attention on products with high overseas market potential, including: 1. PD-1 upgraded products: Sanofi Pharma 2. GLP-1 assets: Lianbang Pharma 3. ADC assets: Kelun Botai, Baile Tianheng - Potential heavyweights for overseas licensing include: 1. PD-1 upgraded products: Kangfang Bio, Innovent Biologics 2. Breakthroughs in autoimmune fields: Yifang Bio, China Antibody 3. Innovative target ADCs: Fuhong Hanlin, Shiyao Group - Products likely to benefit from medical insurance negotiations include: Hengrui Medicine, Kangnuo Pharma, Maiwei Bio, Zhixiang Jintai, and Haichuang Pharma [20] New Drug Approval and Acceptance Status - No new drug or new indication applications were approved this week, but one new drug application was accepted [25] - A total of 117 new drug clinical applications were approved, and 22 new drug clinical applications were accepted this week [10][27]